PTH and Hypocalcemia: Model-based simulations showed that the pediatric cinacalcet starting dose (0.2 mg/kg/day, based on the subject’s dry weight, rounded down to the lowest protocol-specified dose [PSD]), titrated to effect, would provide the desired pharmacodynamic efficacy (PTH suppression > 30%) while minimizing safety concerns (hypocalcemia).